These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

673 related items for PubMed ID: 11341146

  • 1. Drug patent protection: how long is long enough?
    Sibbald B.
    CMAJ; 2001 May 01; 164(9):1331. PubMed ID: 11341146
    [No Abstract] [Full Text] [Related]

  • 2. [Generic medicines].
    Peláez de Loño J.
    Rev Enferm; 1999 Dec 01; 22(12):836-43. PubMed ID: 10797771
    [Abstract] [Full Text] [Related]

  • 3. Lowering the cost of prescription drugs.
    Jindal B.
    J La State Med Soc; 2003 Dec 01; 155(1):51. PubMed ID: 12656276
    [No Abstract] [Full Text] [Related]

  • 4. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE, Ray CJ.
    Expert Opin Ther Pat; 2015 Jan 01; 25(1):1-4. PubMed ID: 25363310
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology.
    Lancet Oncol; 2013 May 01; 14(6):437. PubMed ID: 23639313
    [No Abstract] [Full Text] [Related]

  • 8. The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?
    Silbermann JM.
    J Contemp Health Law Policy; 1996 May 01; 12(2):607-36. PubMed ID: 8666736
    [No Abstract] [Full Text] [Related]

  • 9. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada.
    Openshaw MS.
    Nurs Econ; 2005 May 01; 23(6):307-11, 279. PubMed ID: 16459902
    [Abstract] [Full Text] [Related]

  • 10. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT.
    J Contemp Health Law Policy; 2006 May 01; 22(2):383-408. PubMed ID: 17117702
    [No Abstract] [Full Text] [Related]

  • 11. Running short.
    Mettner J.
    Minn Med; 2011 Oct 01; 94(10):8-10. PubMed ID: 23256277
    [No Abstract] [Full Text] [Related]

  • 12. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS.
    Seton Hall Law Rev; 2003 Oct 01; 33(2):479-510. PubMed ID: 12715807
    [No Abstract] [Full Text] [Related]

  • 13. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug 29; 18(16):6. PubMed ID: 14626916
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
    Becker C.
    Mod Healthc; 2001 Aug 27; 31(35):28-33, 1. PubMed ID: 11550428
    [Abstract] [Full Text] [Related]

  • 17. The ongoing regulation of generic drugs.
    Frank RG.
    N Engl J Med; 2007 Nov 15; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract] [Full Text] [Related]

  • 18. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ, Graham SJ.
    Science; 2009 Oct 16; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract] [Full Text] [Related]

  • 19. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS.
    Food Drug Law J; 1999 Oct 16; 54(2):223-5. PubMed ID: 11759713
    [No Abstract] [Full Text] [Related]

  • 20. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul 16; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.